Boehringer Ingelheim reported Phase 3 results for survodutide, a dual-acting obesity injection, showing substantially greater weight loss than placebo in its Synchronize-1 study. In participants who stayed on treatment for the full 76-week evaluation, survodutide produced up to ~17% mean weight reduction versus ~3% with placebo. The company also reported a key co-primary responder endpoint: up to 85% of treated patients achieved at least 5% weight loss, compared with 39% on placebo. Boehringer said the study also measured body-composition proxies including waist circumference, and it saw signals consistent with weight loss while preserving muscle. Analysts who reviewed the topline described survodutide’s magnitude as broadly comparable to Novo Nordisk’s Wegovy, while short of what’s been seen with Eli Lilly’s Zepbound in separate trials. Boehringer’s next steps include additional detail on safety and more data from a MASH (metabolic dysfunction–associated steatohepatitis) trial that could affect future positioning in cardiometabolic care.